GC
HRMY icon

Guggenheim Capital’s Harmony Biosciences HRMY Stock Holding History

Guggenheim Capital’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$216K Sell
7,720
-16,390
-68% -$537K ﹤0.01% 1503
2025
Q4 		$902K Buy
+24,110
New +$793K 0.01% 996

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Guggenheim Capital's HRMY Position: Q1 2026 in Review

Guggenheim Capital reduced its Harmony Biosciences (HRMY) stake by 68% in Q1 2026, selling an estimated $537K and leaving 7,720 shares worth $216K. The position accounts for ﹤0.01% of the portfolio, ranked #1503.

Guggenheim Capital first reported a position in HRMY in Q4 2025 and has held it in 2 quarters since. The position peaked at $902K in Q4 2025. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Guggenheim Capital held 7,720 shares of Harmony Biosciences worth $216K as of Q1 2026.
  • Guggenheim Capital sold 16,390 Harmony Biosciences shares in Q1 2026, an estimated $537K.
  • Harmony Biosciences made up ﹤0.01% of Guggenheim Capital's portfolio in Q1 2026, its #1503 holding.
  • Guggenheim Capital first reported a position in Harmony Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Guggenheim Capital's Harmony Biosciences position peaked at $902K in Q4 2025.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.